Results 131 to 140 of about 81,306 (284)
Oxaliplatin-Related Ocular Toxicity
, 2010 We report the case of a 52-year-old woman with advanced colorectal cancer who was treated with oxaliplatin on a FOLFOX schedule. After 3 cycles of chemotherapy, she started to complain of visual loss, altered color vision and neurological symptoms.
Marc Figueras-Roca +7 more
core +1 more source
Interdisciplinary Medicine, EarlyView.Liquid biopsy uses non‐invasive sampling of blood or body fluids to isolate circulating analytes, including circulating tumor DNA, circulating tumor cells, extracellular vesicles, and RNA. These are analyzed using next‐generation sequencing, qPCR, and proteomics to inform cancer detection, monitoring, and characterization. Figure created with BioRender.
Jaswinder Singh +2 more
wiley +1 more source
Journal of Applied Toxicology, EarlyView.ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü +3 more
wiley +1 more source
Oxaliplatin-Induced Tonic-Clonic Seizures
, 2015 Oxaliplatin is a common chemotherapy drug used for colon and gastric cancers. Common side effects are peripheral neuropathy, hematological toxicity, and allergic reactions.
Phu V. Truong +2 more
core +1 more source
Journal of Applied Toxicology, EarlyView.ABSTRACT Oxaliplatin is a platinum‐based anticancer agent widely used for gastrointestinal malignancies; however, it is known to cause dose‐dependent peripheral neuropathy (OIPN), a characteristic adverse effect. OIPN results in a reduced quality of life and often necessitates dose reduction or discontinuation of oxaliplatin; however, effective ...
Yusuke Koura +11 more
wiley +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Introduction The PRODIGE 24/CCTG PA.6‐ trial has shown an overall survival (OS) up to 55 months in patients treated with (modified) 5‐fluorouracil, leucovorin, irinotecan and oxaliplatin ((m)FOLFIRINOX) chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC). The applicability of these results to a real‐world patient population
N. C. Biesma +7 more
wiley +1 more source
Mass Spectrometry Reviews, EarlyView.ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley +1 more source
Iranian Journal of Allergy, Asthma and Immunology, 2009 Oxaliplatin, a third generation of platinum-based anti-neoplastic agent has been approved for colorectal cancer in both adjuvant and metastatic settings.
Jia Li +2 more
doaj
Organoid Coculture Models for Cancer Research and Immunotherapy
Med Research, EarlyView.This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang +9 more
wiley +1 more source
Some aspects of liposomal oxaliplatin formulations [PDF]
, 2015 Methods for creations of oxaliplatin liposomal form in laboratory scale are discussed in this mini-review. Analysis of existed methods has been carried out, and the estimation of their usage in pharmaceutical industry view has been given.
V. I. Shvets +2 more
core